<DOC>
	<DOCNO>NCT01657305</DOCNO>
	<brief_summary>The main purpose phase III clinical trial show safety efficacy Oleogel-S10 acceleration Split-Thickness Skin Graft Donor Sites .</brief_summary>
	<brief_title>Oleogel-S10 Wound Healing Split-Thickness Skin Graft Donor Sites</brief_title>
	<detailed_description>Oleogel-S10 show efficacy well tolerate previous clinical trial patient skin lesion . Especially result previous study split-thickness skin graft donor site suggest Oleogel-S10 efficacious safe treatment superficial wound . The present phase III clinical trial grade split-thickness skin graft donor site initiate order demonstrate measure wound heal progress apply objective method , i.e. , time heal grade epithelialization wound . In study , split-thickness skin graft donor site separate two wound half . Randomly assign , one wound half receive Oleogel-S10 ointment , wound half standard care treatment . Wound heal progress document photo assess expert reviewer blind treatment wound half .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>Presenting splitthickness skin graft donor site wound minimum size 15 cm2 minimum width 3 cm . Patient able understand ICF provide prepared comply study requirement , include follow : Visiting trial site wound dress change photo documentation every third fourth day wind half close ( longer 28 day surgery ) . Willing perform necessary wound dress change trial site . Also patient need agree return site 3 12 month followup visit . Women childbearing potential must apply highly effective method birth control ( failure rate le 1 % per year use consistently correctly ( e.g. , implant , injectables , combine oral contraceptive , intrauterine contraceptive device ( IUDs ) , sexual abstinence , vasectomized partner ) ) . Diseases condition could , opinion Investigator , interfere assessment safety efficacy . A skin disorder chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial . A history clinically significant hypersensitivity drug , surgical dressing excipients use trial . Known multiple allergic disorder . Taking , take , investigational drug within 3 month prior screen visit . Pregnant breast feed woman allow participate study . Inappropriate participate study , reason , opinion investigator . Mental incapacity language barrier preclude adequate understanding Informed consent form cooperation willingness follow study procedure . Previous participation study . Employee investigational site , relative spouse investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Split-Thickness Skin Graft Donor Site</keyword>
	<keyword>Split-thickness skin graft</keyword>
	<keyword>STSG</keyword>
	<keyword>Wound heal</keyword>
	<keyword>Skin grafting</keyword>
	<keyword>Superficial wound</keyword>
	<keyword>Partial-thickness wound</keyword>
	<keyword>Time wound closure</keyword>
</DOC>